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Synthetic cannabinoid receptor agonists (SCRAs) have been the largest group of
illicit psychoactive substances reported to international monitoring and early warning
systems for many years. Carboxamide-type SCRAs are amongst the most prevalent and
potent. Enantiospecific synthesis and characterization of four indazole-3-carboxamides,
AMB-FUBINACA, AB-FUBINACA, 5F-MDMB-PINACA (5F-ADB), and AB-CHMINACA
is reported. The interactions of the compounds with CB1 and CB2 receptors
were investigated using a G-protein coupled receptor (GPCR) activation assay
based on functional complementation of a split NanoLuc luciferase and EC50
(a measure of potency) and Emax (a measure of efficacy) values determined.
All compounds demonstrated higher potency at the CB2 receptor than at the
CB1 receptor and (S)-enantiomers had an enhanced potency to both receptors
over the (R)-enantiomers. The relative potency of the enantiomers to the CB2
receptor is affected by structural features. The difference was more pronounced
for compounds with an amine moiety (AB-FUBINACA and AB-CHMINACA) than
those with an ester moiety (AMB-FUBINACA and 5F-MDMB-PINACA). An HPLC
method was developed to determine the prevalence of (R)-enantiomers in seized
samples. Lux® Amylose-1 [Amylose tris(3,5-dimethylphenylcarbamate)] has the greatest
selectivity for the SCRAs with a terminal methyl ester moiety and a Lux®
i-Cellulose-5 column for SCRAs with a terminal amide moiety. Optimized isocratic
separation methods yielded enantiomer resolution values (Rs) ≥ 1.99. Achiral
GC-MS analysis of seized herbal materials (n = 16), found 5F-MDMB-PINACA
(<1.0–91.5 mg/g herbal material) and AMB-FUBINACA (15.5–58.5 mg/g herbal
material), respectively. EMB-FUBINACA, AMB-CHMICA, 5F-ADB-PINACA isomer 2, and
Antonides et al. Characterizing Synthetic Cannabinoid Receptor Agonists
ADB-CHMINACA were also tentatively identified. Analysis using chiral chromatography
coupled to photodiode array and quadrupole time of flight mass spectrometry
(chiral HPLC-PDA-QToF-MS/MS) confirmed that the (S)-enantiomer predominated in
all samples (93.6–99.3% (S)-enantiomer). Small but significant differences in synthesis
precursor enantiopurity may provide significant differences between synthesis batches
or suppliers and warrants further study. A method to compare potency between samples
containing different SCRAs at varying concentrations was developed and applied in this
small preliminary study. A 10-fold difference in the “intrinsic” potency of samples in the
study was noted. With the known heterogeneity of SCRA infused materials, the approach
provides a simplified method for assessing and communicating the risk of their use.
Keywords: synthetic cannabinoid receptor agonists, chiral, pharmacology, bioassay, detection
INTRODUCTION
Synthetic cannabinoids (SCs) are the most chemically diverse
group of new psychoactive substances (NPS) reported to national
and international drug early warning systems (EMCDDA,
2018a; UNODC, 2018a). Synthetic cannabinoid receptor agonists
(SCRAs) are cannabimimetics, exerting their pharmacological
effects through human cannabinoid type 1 and type 2 (CB1
and CB2) G-Protein Coupled Receptors (GPCRs). Due to their
structural diversity they exhibit a wide range of receptor binding
and activation properties and therefore have a wide range of
potency and efficacy. CB1 receptors, present primarily in the
central nervous system and to a lesser extent in the peripheral
tissues, mediate the psychoactive effects associated with SCRAs
whilst CB2 receptors are expressed primarily in the immune
system (Pertwee, 1997, 2008; Pertwee et al., 2010). CB1 and CB2
receptor agonists are recognized for their potential as therapeutic
agents (Han et al., 2013). As a result, many SCRA classes
and hundreds of analogs have been synthesized and studied as
pharmacological targets by research groups across academia and
industry. These compounds have often been found to bind to
and activate both receptors and, as a result of their psychoactive
effects, few have reached clinical trials and have been developed
asmedicinal products (e.g., Huffman and Padgett, 2005; Huffman
et al., 2005; Huffman, 2009; Han et al., 2013). Synthetic routes
have been patented and published and SCRA receptor binding
and activation data reported as a result of structure activity
relationship (SAR) studies (e.g., Huffman et al., 2005; Buchler
et al., 2009). With the crystal structure of the CB1 and CB2
receptors having recently been described (Hua et al., 2016; Kumar
et al., 2019; Li et al., 2019; Lorenzen and Sakmar, 2019), the study
of the influence of the absolute structural conformation of SCRAs
on cannabinoid receptor binding and activation via agonist-
initiatedGPCR ligand-receptor complex induced conformational
changes continues (Ibsen et al., 2017; Schoeder et al., 2018;
Kumar et al., 2019). Due to variations in their molecular
structure, different SCRAs may cause different conformational
changes in the receptor-ligand complex conformation and as
a result give rise to different cellular responses with a bias
to a particular signaling pathway (e.g., G-protein coupling
vs. β-arrestin recruitment). In opioid receptors, such biased
signaling has been utilized to create agonists which are biased
toward pathways which give rise to desired therapeutic effects
rather than those which give rise to unwanted side effects
(Ho et al., 2018).
In parallel to an increasing understanding of the interaction
of SCRAs with cannabinoid receptors, the illicit drugs market
continues to search for, produce, and supply potent CB1-selective
or mixed selectivity SCRAs for their psychoactive effects. SCRAs
have been involved in an increasing number of fatal and non-fatal
intoxications globally (e.g., Shevyrin et al., 2015; Adamowicz,
2016; Gieron and Adamowicz, 2016; Adams et al., 2017;
Angerer et al., 2017; EMCDDA, 2018b; Kronstrand et al., 2018).
Reported adverse health effects include agitation, psychosis,
anxiety, tachycardia, seizures, and hypothermia (Sherpa et al.,
2015; Adams et al., 2017) and in rodent studies many of these
effects have been shown to be CB1-receptor mediated (e.g.,
Banister et al., 2013, 2015b, 2016; Funada and Takebayashi-
ohsawa, 2018; Wilson et al., 2019), however the influence
of different signaling pathways on these effects has not yet
been established.
The pharmacology of these substances has been
studied in a responsive and at times, pre-emptive
manner (Banister et al., 2015a, 2016, 2019b; Cannaert
et al., 2016; Longworth et al., 2017; Schoeder et al.,
2018; Noble et al., 2019). The origins and evolution
of SCRAs from medical research tools and drug
candidates to often highly potent illicit drugs have
recently been extensively and elegantly reviewed
(Banister and Connor, 2018a,b).
On the illicit market, SCRAs are commonly bought as
crystalline solids or viscous liquids and dissolved in solvents
such as acetone and alcohols for spraying or mixing with
plant materials. In this way the final product mimics the
visual characteristics of herbal cannabis, and such materials are
then sold as herbal smoking mixtures, known collectively and
colloquially as “spice” (Pützl et al., 2015; EMCDDA, 2017a).
This often gives rise to heterogeneous final products, making
consistent dosing difficult for users and therefore producing
unpredictable effects (Moosmann et al., 2015; Frinculescu
et al., 2017). There has been a considerable diversification of
the products in which such compounds have been detected,
Frontiers in Chemistry | www.frontiersin.org 2 May 2019 | Volume 7 | Article 321
Antonides et al. Characterizing Synthetic Cannabinoid Receptor Agonists
including powders, e-liquids for vaping (Peace et al., 2017;
Angerer et al., 2019), impregnated papers and letters (Ford and
Berg, 2018), clothing and other materials. These latter forms are
commonly associated with the smuggling of SCRAs into prisons
where they are particularly prevalent (EMCDDA, 2017a, 2018c;
National OffenderManagement Service, 2017; Ralphs et al., 2017;
Metternich et al., 2019).
The types of SCRAs detected have evolved in response
to market demand, research studies on analog potency and
national and international legislative controls. Arguably the
most important controls are those controlling production
and supply in China, with clear evidence that this is the
main point of origin for such substances. In 2015, the
production and export of 116 NPS were controlled by China
including 39 SCRAs (UNODC, 2015) and soon after many
of these, if not all, disappeared from the market. These
compounds were rapidly replaced by new analogs, and in
many but not all cases, these new substances have generally
been more potent (Banister and Connor, 2018b; Banister
et al., 2019a,b; Noble et al., 2019). It is therefore important
to develop robust and adaptable methodologies to carry
out detailed analytical and pharmacological profiling of new
substances as they appear on the illicit drug market and
to determine the relative theoretical potency of materials
containing SCRAs at all levels of the supply chain for harm
reduction purposes.
In recent years, SCRAs with acylindole and acylindazole
scaffolds have become amongst the most prevalent and potent
available on illicit markets. Relevant chemical structures
discussed in this study are provided in Figure 1 and numbers in
bold parentheses, e.g., (1), refer to these structures throughout
the text. The most common of these compounds in recent
years have been some of the many analogs developed by
Pfizer Global Research & Development and patented in 2009
as potential analgesics (Buchler et al., 2009; Banister et al.,
2015a; Banister and Connor, 2018a). The valine- and tert-
leucine derived indazole-3-carboxamide analogs are chiral
molecules and can therefore theoretically be present in two
enantiomeric forms. Their relative prevalence will depend
upon the source of the precursor chemicals used and their
enantiopurity. Amongst a wide array of other compounds,
the original Pfizer patent (Buchler et al., 2009) utilized L-tert-
leucine methyl ester, L-valinamide and L-leucinamide to give
(S)-enantiomer products [e.g., (S)-AB-FUBINACA (1) (N-(2S)-
(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-
indazole-3-carboxamide], (S)-AMB-FUBINACA (2) methyl
(2S)-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-
3-methylbutanoate, (S)-AB-CHMINACA (4) (N-(2S)-(1-
amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-
1H-indazole-3-carboxamide) and (S)-ADB-FUBINACA
(5) (N-(2S)-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-
fluorobenzyl)-1H-indazole-3-carboxamide)). No assessment
of enantiopurity of precursors or products was reported and
no synthesis methods or pharmacological data for the possible
(R)-enantiomers were published (Buchler et al., 2009). This
group of compounds also lead to the arrival of some of the
most potent SCRAs to be seen on the illicit market, including
5F-MDMB-PINACA ((3), more commonly referred to as
5F-ADB) and MDMB-FUBINACA (20).
There is a growing interest in the chromatographic
separation of the increasing diversity of chiral NPS (as well
as more traditional drugs of abuse such as amphetamine
and methamphetamine), to gain additional information
on the synthetic routes used in their manufacture and to
indicate their inherent potency and efficacy (Taschwer et al.,
2017; Kadkhodaei et al., 2018; Silva et al., 2018). There are
opportunities to add chiral profiling to existing drug profiling
methodologies if there is reproducible variation in the chiral
profiles of precursor materials, even if the absolute differences
are small. Chiral profiling can also aid in the assessment of
a seized material’s potency and therefore in risk assessment
and harm reduction strategies. Using a Diacel Chiralpak R©
AZ-3R column, Doi et al. (2016, 2018) reported the reverse
phase HPLC separation of a number of carboxamide-type
SCRA enantiomers (5F-AB-PINACA (7) (N-(1-amino-3-
methyl-1-oxo-2-butanyl)-1-(5-fluoropentyl)-1H-indazole-3-
carboxamide), AB-FUBINACA 2-fluorobenzyl isomer (8)
(N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(2-fluorobenzyl)-
1H-indazole-3-carboxamide), APP-CHMINACA (9) (N-(1-
amino-1-oxo-3-phenylpropan-2-yl)-1-(cyclohexylmethyl)-1H-
indazole-3-carboxamide), EMB-FUBINACA (10) (ethyl 2-(1-(4-
fluorobenzyl)-1H-indazole-3-carboxamido-3-methylbutanoate),
5F-EMB-PINACA (11) (ethyl 2(-1-(5-fluoropentyl)-1H-
indazole-3-carboxamido)-3-methylbutanoate), MDMB-
FUBICA (14) (methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-
carboxamido)-3,3-dimethylbutanoate) and 5F-AMB (15)
(methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carbamido)-3-
methylbutanoate). The separation of MDMB-CHMICA (12)
(methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido-
3,3-dimethyl-butanoate) and MDMB-CHMCZCA (13) (methyl
2-(9-(cyclohexylmethyl)-9H-carbazole-3carboxamido)-3-
methylbutanoate) enantiomers using a Chiralpak R© IA-3 column
in normal phase mode has also been reported (Andernach et al.,
2016; Weber et al., 2016).
This study describes the enantiospecific synthesis and
chemical and pharmacological characterization of four indazole-
3-carboxamide SCRA enantiomer pairs (AB-FUBINACA
(1), AMB-FUBINACA (2) 5F-MDMB-PINACA (3) and AB-
CHMINACA (4)). All four SCRAs have been detected in seized
samples and two, AMB-FUBINACA and 5F-MDMB-PINACA,
have been amongst the most prevalent compounds detected
in Europe, particularly in the UK, and the United States for
several years (EMCDDA, 2017b, 2018a,b; Centre for Forensic
Science Education, 2018; DEA, 2018a,b). In September 2018,
a ban on the production and export of seven of the most
potent SCRAs, including AMB-FUBINACA (2) and 5F-MDMB-
PINACA (3) was announced by the Chinese Government1
(UNODC, 2018b). This could lead, as previously observed
with the earlier 39 SCRAs controlled in a similar way in
2015, to their rapid disappearance from the illicit market.
In the same way they are likely to be replaced either by
1https://www.thepaper.cn/newsDetail_forward_2389954 (accessed February 2,
2019)
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FIGURE 1 | Structures of the indazole-3-carboxamide synthetic cannabinoids utilized in this study and in previous studies. (1) AB-FUBINACA; (2) AMB-FUBINACA;
(3) 5F-MDMB-PINACA (5F-ADB); (4) AB-CHMINACA; (5) (S)-ADB-FUBINACA; (6) (S)-AB-PINACA; (7) (S)-5F-AB-PINACA; (8) AB-FUBINACA 2-fluorobenzyl isomer;
(9) APP-CHMINACA; (10) EMB-FUBINACA; (11) 5F-EMB-PINACA (12) MDMB-CHMICA; (13) MDMB-CHMCZCA (14) MDMB-FUBICA; (15) 5F-AMB; (16)
AMB-CHMICA (MMB-CHMICA); (17) ADB-CHMINACA (MAB-CHMICA); (18) (1S,2S)-5F-ADB-PINACA isomer 2. (19) JWH-018; (20) MDMB-FUBINACA. *Indicates
the position of the chiral centre.
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completely new analogs or by similar chiral compounds with
small structural alterations, e.g., their azaindole analogs, or
modifications to the N-alkyl/benzyl chain where the length
and/or position of the substituent (normally fluorine) is varied.
Such compounds include the recently reported chiral SCRAs,
4F-MDMB-BINACA (methyl 2-((1-(4-fluorobutyl)indazole-3-
carbonyl)amino)-3,3- dimethyl-butanoate), 5F-MDMB-PICA
(Centre for Forensic Science Education, 2019), 5F-AB-P7AICA
(N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-
1H-pyrrolo[2,3-b]pyridine-3-carboxamide) (Adebar Project,
2018) and APP-BINACA (N-(1-amino-1-oxo-3-phenylpropan-
2-yl)-1-butyl-1H-indazole-3-carboxamide) (EMCDDA, 2019).
The rapid and efficient synthesis of enantiopure reference
standards and the development of robust separation methods for
their ongoing monitoring and evaluation is therefore required
to facilitate full analytical and pharmacological assessment.
Although there has to date been relatively little variation in
the SCRA chiral profiles reported in the literature, the number
of samples that have been tested is small and there is not yet
an understanding of the variability and reproducibility of the
small but potentially discriminatory differences between batches
and/or precursor suppliers. An underlying understanding of
the chiral separation mechanisms provides the ability to adapt
methods rapidly to the inevitable arrival of new chiral SCRAs or
the resurgence of others not yet under such control.
This study also reports the relative potency and efficacy
of the SCRAs described using previously reported stable cell-
based assays that monitor CB1 and CB2 receptor activation
and are based on the recruitment of the cytosolic protein, β-
arrestin 2 (βarr2) to the activated receptor. The methodology
has previously been applied to both pure compounds and
toxicological samples and has recently been fully validated
(Cannaert et al., 2016, 2017, 2018, 2019a,b; Noble et al., 2019) and
will be used to gain further insights into SCRA pharmacology in
the light of recent studies (e.g., Kumar et al., 2019). A comparative
approach for the assessment of street and prison seized SCRA
samples, combining the determination of SCRA concentrations
and where possible including the elucidation of chiral profiles
considers the concept of “estimated intrinsic potency” of a
sample is introduced. Such an approach could provide a more
logical way to assess the potential for harm and to communicate
risk effectively in a context where individual SCRA compounds
vary widely in structure and potency and vary geographically
and temporally.
MATERIALS AND METHODS
Chemicals
Reagents for the synthesis of the enantiopure reference
standards (see Figure 2) were obtained from Sigma-Aldrich,
Gillingham, UK; Alfa Aesar, Heysham, Lancashire, UK; and
Fluorochem Limited, Hadfield, UK, and were used without
further purification. Custom synthesized D-tert-leucine was
supplied by Carbosynth, UK. Solvents used in the synthesis
(including deuterated solvents) were acquired from Sigma-
Aldrich or Thermo Fisher Scientific, Loughborough, UK. All
solvents used for HPLC and GC-MS analysis were HPLC
grade and supplied by Fisher, UK. Ultra-high purity water
(18 Mcm−1) was obtained using a Milli-Q water purification
system (Merck, UK).
Enantiospecific Synthesis
The N-substituted indazole-3-carboxylic acids were synthesized
following procedures previously reported in the literature
(Banister et al., 2015a, 2016) or adaptations of them (Figure 2).
The synthesis of AB-CHMINACA was based on the synthesis
of AMB-CHMINACA with valinamide being substituted for the
valine methyl ester (see Figure 2) and the synthesis optimized
by the addition of another equivalent of potassium tert-butoxide
and bromomethyl cyclohexane and the reaction being heated to
a reflux for 18 h instead of being stirred at room temperature for
48 h as described in the original method.
Reference Standard Characterization
Nuclear magnetic resonance (NMR) spectroscopy
NMR spectroscopy for the 5F-MDMB-PINACA, AB-
FUBINACA and AMB-FUBINACA enantiomers was performed
using a JEOL ECS-400 NMR spectrometer (JEOL, Tokyo,
Japan) operating at 400 MHz. 1H-NMR (10 mg/mL in CDCl3),
13C-NMR (20 mg/mL in CDCL3). NMR spectroscopy for the
AB-CHMINACA enantiomers was performed using a Bruker
AVANCE III HD 500 MHz spectrometer (Bruker, Billerica,
MA, USA) running under TopSpin v.3.2.5 and equipped with
a QCI-F cryo-probe at a sample compartment temperature of
25◦C. Samples were prepared in CDCl3 (∼10 mg/mL).
Gas chromatography-mass spectrometry (GC-MS)
GC-MS analysis of reference standards (100–1,000µg/mL)
and seized sample extracts was carried out using a 7820A
gas chromatograph coupled to a 5977E mass spectrometer
(Agilent Technologies, Santa Clara, CA, USA). Injection mode:
1 µL sample injection and 20:1 split (and a 5:1 split for
trace component screening), injection port temperature: 200◦C,
carrier gas: He, flow: 1 mL/min. Column: DB-1MS, 0.33µm,
0.2mm × 25m (Agilent Technologies) (EMCDDA, 2017d). GC
oven: 80◦C held for 3min; 40◦C/min to 300◦C held for 3.5min;
transfer line: 295◦C. The mass spectrometer operated in electron
ionization (EI) mode. Ionization conditions: 70 eV in full scan
mode (50–550 amu), ion source: 230◦C, quadrupole: 150◦C.
High performance liquid chromatography with photodiode
array detection (HPLC-PDA)
Initial chiral column screening was carried out using an Agilent
Infinity II HPLC system with photodiode array detection
(PDA). The selectivity of Lux R© Amylose-1, Lux R© Cellulose-1-
4 columns (all 5µm, 4.6 × 100mm) and a Lux R© i-Cellulose-
5 column (5µm, 4.6 × 150mm column) from Phenomenex,
UK, were assessed by triplicate 5µL injections of a 0.2mg/mL
SCRA racemic mixture standards using 50:50 MilliQ H2O (A)
: ACN (B) with a flow rate of 1.0 mL/min. The two most
selective chiral stationary phases (CSPs) were identified and
optimized column formats selected (Lux R© Amylose-1, 3µm,
2.1 × 150mm and Lux R© i-Cellulose-5, 3µm, 2.1 × 150mm).
To assess their chromatographic performance in more detail,
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FIGURE 2 | Enantiospecific synthesis of eight indazole-3-carboxamide synthetic cannabinoids. Compound numbering relates to that provided in Figure 1.
triplicate 1 µL injections of a 200µg/mL reference standard
solution in both acetonitrile and methanol were made in
isocratic mode at 45:55, 50:50, and 55:45 (A:B) with a flow
rate of 0.2 mL/min. After optimization and after assessing
the SCRAs known to be present in the seized samples to be
analyzed, the Lux R© Amylose-1 column was used for the analysis
of seized samples.
High performance liquid chromatography-photodiode
array-quadrupole time of flight mass spectrometry
(HPLC-PDA-QToF-MS/MS)
High resolution mass spectrometry (HRMS) analysis of the
synthesized reference standards and seized samples was
performed using an Acquity UPLC R© instrument consisting of a
binary pump, autosampler (held at 4◦C), vacuum degasser and
column oven (held at 30◦C), coupled to a Xevo-QToF-MS/MS
(Waters Corporation, Milford, MA, USA). Mobile phases
were (A) LC-MS grade water with 0.1% formic acid and (B)
acetonitrile with 0.1% formic acid. Flow rate was 0.2 mL/min and
1 µL of sample was injected onto a Lux Amylose-1, 3µm, 2.1 ×
150mm, column. The QToF was operated in positive ionization
mode with a source temperature of 120◦C, a desolvation
temperature at 500◦C and a capillary voltage at 2.25 kV. ToF-MS
analysis for the high-resolution determination of molecular
mass and calculation of mass error (ppm) was carried out with
a collision energy at 6V. MSe aquisition was carried out using
collision energies ranging from 6 to 28V. Once QTOF-MS, and
MSe data were processed, MS/MS data acquisition was utilized
for selected parent ion accurate mass data to provide accurate
product ion data. UV spectra (200–400 nm) were collected using
an Acquity R© PDA detector.
Cannabinoid Receptor Assay
To assess the biological activity of the synthesized reference
compounds, live cell-based reporter assays that monitor protein-
protein interactions via NanoLuc Binary Technology were
used as described previously (Cannaert et al., 2018). The
receptor activation is evaluated via the interaction between
βarr2, a cytosolic protein, and the GPCRs CB1 and CB2.
Both βarr2 and CB1/CB2 are fused to an inactive part of
nanoluciferase. When CB1 or CB2 are activated by a ligand,
βarr2 is recruited to the receptor, allowing interaction of the
complementary nanoluciferase subunits, yielding a functional
enzyme that generates a bioluminescent signal in the presence
of the substrate furimazine. Curve fitting and statistical analyses
were performed using GraphPad Prism software (San Diego,
CA, USA). The results are represented as mean area under
the curve (AUC) ± standard error of mean (SEM) with at
least seven replicates for each data point (obtained in three
independent experiments). Curve fitting of concentration-effect
curves via non-linear regression (four parameter logistic fit) was
employed to determine EC50 (measure of potency) and Emax
values (measure of efficacy). The Emax values are normalized to
the Emax value of JWH-018 (100%).
Seized Samples
Suspected SCRA samples, all in clear plastic “Snap bags”
containing herbal material purported to be “spice” were seized
by Greater Manchester Police (GMP) in Piccadilly Gardens,
Manchester, UK between 21 March 2017 and 15 January 2018.
They are provided to this study via the MANchester DRug
Analysis and Knowledge Exchange (MANDRAKE) partnership
between GMP and Manchester Metropolitan University. All
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bulk samples had previously undergone preliminary qualitative
analysis prior to inclusion in this study.
Seized Sample Analysis
Qualitative and Quantitative Achiral GC-MS Analysis
For each SCRA sample, three replicate aliquots of approximately
10mg herbal material were accurately weighed out. Each 10mg
aliquot was extracted sequentially using 3 × 1mL of 75:25
dichloromethane:methanol with 10min ultrasonication, after
which the three extracts were combined. A 200 µL aliquot of
this extract was diluted to 1mL using an internal standard
(tridecane) solution in 75:25 dichloromethane:methanol to give
a final internal standard concentration of 35.5µg/mL. For
trace component screening, 50mg of sample was extracted by
sonication for 10min with 1mL methanol. The four indazole-
3-carboxamide SCRAs for which in house reference standards
were synthesized were identified by comparison of retention
times and mass spectra between the seized samples and the
reference standards. Confirmation of analyte identity was made
by reference to the Cayman spectral library (version 12212018)
and SWGDRUG spectral library (version 3.3) with a minimum
reverse match score of 800 required for identification. SCRA
concentrations are provided as an average concentration (mg/g)
and range, reflecting the heterogeneous nature of the herbal
materials (the samples were purposefully not homogenized to
retain this information). Other SCRAs detected, for which
reference standards were not available in house, were tentatively
identified by reference to the mass spectral libraries with
corroboration provided by HPLC-QToF-MS/MS spectra and
reference to previously published HRMS spectra. A series of
calibration standards were prepared and used to generate non-
linear calibration curves (R2 > 0.99) for the quantitation of
5F-MDMB-PINACA and AMB-FUBINACA in seized herbal
samples (10 to 200µg/mL, each with 35µg/mL tridecane as
internal standard). The precision of the instrument and accuracy
of the calibration curve was verified by the replicate (n =
12) analysis of an independent calibration check standard
(30µg/mL), yielding a coefficient of variance (CV) of 3.6
and 3.0% and bias of +3.2 and −4.6% for 5F-MDMB-
PINACA and AMB-FUBINACA, respectively. The estimated
concentrations of the SCRAs present in seized samples for
which in house reference standards were not available were
calculated using the detector response for AMB-FUBINACA
and these are clearly noted in the text and figures as
semi-quantitative results.
Qualitative Chiral UPLC®-PDA-QToF-MS/MS Analysis
Approximately 50mg of seized sample was accurately weighed
out and sequentially extracted using 3 × 1mL of methanol. The
extracts were combined and filtered using a 0.45µm syringe filter
prior to transferring a 1mL aliquot to a 2mL sample vial. Further
dilutions (10x, 100x, and 1,000x) were prepared to establish the
linearity of the PDA andMS/MS detector response. Enantiomeric
ratios were determined by integration of the UV chromatogram
at 210 nm.
RESULTS AND DISCUSSION
In a drug misuse and harm reduction setting, understanding
the relative potency (and therefore potential effects and harms)
of different drug batches or drug presentations is of critical
importance. In legal terms, for a seized bulk drug or drug
product, the identification of the substance(s) present will be
of paramount importance to determine legality. In addition,
any information that may facilitate batch linkage and source
identification is also worthy of study. The relative potency of
a particular SCRA containing product will be related to (i)
the type(s) of SCRAs present within the sample and (ii) the
concentrations of those SCRAs.
Synthesis
(S)- and (R)-enantiomers of four indazole-3-carboxamide
SCRAs (AB-FUBINACA (1), AMB-FUBINACA (2), 5F-MDMB-
PINACA (3) and AB-CHMINACA (4)) were successfully
synthesized. With the exception of 5F-MDMB-PINACA, (R)-
enantiomers of these SCRAs are not currently commercially
available. All enantiopure standards were calculated to have
an enantiopurity of >99.8% by GC-MS and HPLC-PDA,
NMR and HRMS data. Full characterization data (NMR, GC-
MS, HPLC-QToF-MS/MS, UV) for all enantiopure reference
standards were similar between enantiomer pairs and in
agreement with their expected structures and are provided in the
Supplementary Information.
Activity-Based Receptor Bioassay Results
We compared the potencies of all synthesized reference standards
at CB1 and CB2 receptors (Table 1, Figure 3). All eight
compounds (four enantiomer pairs) activated CB1 and CB2
receptors as would be expected from previous studies on the
(S)-enantiomers of these compounds. (S)-AB-FUBINACA had
previously been analyzed using the same bioassay (Noble et al.,
2019) and results between the two analyses were consistent as
were the data for the positive control compound (JWH-018). All
(S)-enantiomers had higher potency (EC50) and efficacy (Emax)
values at CB1 than the control JWH-018 (2.5–3.4 times Emax),
which is commonly described as a full agonist, as did the (R)-
enantiomers of 5F-MDMB-PINACA and AMB-FUBINACA (1.5
and 1.8 times JWH-018 Emax), suggesting that these compounds
strongly and/or stably recruit βarr2 to CB1 in comparison to
JWH-018. The high CB1 efficacy values of the (S)-enantiomers
compared to JWH-018 obtained from this assay, might suggest
that the assay ceiling has not yet been met. This could be tested
in future studies by determining the relative efficacy of the high
efficacy SCRAs before and after depleting the receptor reserve
with an irreversible CB1 antagonist, such as AM6544 (Sachdev
et al., 2018). For each enantiomer pair, the (S)-enantiomer
was considerably more potent than the corresponding (R)-
enantiomer, in agreement with the only other previous study for
related indazole-3-carboxamides (Doi et al., 2018). The difference
in potency between enantiomer pairs was less pronounced for
CB2 than CB1 as has previously been observed previously. For
CB1 the differences ranged from 6.11- to 114-fold depending
on the enantiomer pair, and for CB2 1.55- to 63.5-fold. The
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FIGURE 3 | EC50 curves of indazole-3-carboxamide synthetic cannabinoids for (A) CB1 and (B) CB2 receptors. Each data point represents the mean value and error
bars represent the standard error of the mean (SEM) for at least seven replicates (obtained in 3 independent experiments). Compound numbering relates to that
provided in Figure 1.
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relative potency of the enantiomers to the CB2 receptor is affected
by structural features, the difference being more pronounced
for compounds with an amine moiety (AB-FUBINACA and
AB-CHMINACA) than those with an ester moiety (AMB-
FUBINACA and 5F-MDMB-PINACA).
With an EC50 of 1.78 nM (Table 1), (S)-5F-MDMB-PINACA
(3) has the highest potency at CB1 of all the compounds
tested in this study, followed by the (S)-enantiomers of
AMB-FUBINACA >AB-CHMINACA >AB-FUBINACA. The
potency of (S)-5F-MDMB-PINACA is second only to (S)-
ADB-FUBINACA previously tested using the same bioassay
under the same conditions (Noble et al., 2019). (S)-5F-MDMB-
PINACA was four times more potent at CB1 than (S)-AMB-
FUBINACA (4), consistent with previously reported data using
the FLIPR assay which measures changes in membrane potential
(Banister et al., 2015b).
(R)-AMB-FUBINACA tested in this study was more potent
than any other (R)-enantiomer in this study and was more
potent than both the indazole-3-carboxamides, (S)-JWH-018
(control, this study) and (S)-AB-PINACA (6) and the indole-
3-carboxamides 5F-AMB-PICA and 5F-PY-PICA analyzed
previously using the same assay under the same conditions
(Noble et al., 2019). The latter compound has been found
to have little or no CB1 activity, a finding confirmed by
Banister et al. (2019a).
AB-FUBINACA (1), with a terminal amide moiety
(valinamide), and AMB-FUBINACA (2), with a terminal
methyl ester (valinate) moiety, are otherwise structurally
identical, both having a para-fluorobenzyl moiety linked to
the indazole core. The (S)-enantiomers have a similar potency
at CB1 but exhibited a marked difference in the EC50 ratio
between (S) and (R) enantiomers between the compounds.
For AMB-FUBINACA (2) the (S)-enantiomer was 6.1 times
as potent as the (R)-enantiomer whilst for AB-FUBINACA
(3) the (S)-enantiomer was >100 times more potent than the
(R)-enantiomer. This difference may be explained by differential
interactions between the enantiomer pairs and the CB1 receptor,
at the valinamide and valinate moieties.
Using the structurally similar and highly potent SCRA,
MDMB-FUBINACA (20), Kumar et al. (2019) demonstrated that
the indazole group and p-fluorobenzyl moiety is most likely
involved in hydrophobic interactions with receptor elements,
the latter within a conserved docking region (described as
a narrow side pocket). It is suggested that this narrow
pocket is an important region influencing ligand affinity rather
than activation whilst the indazole region influences receptor
activation and therefore more clearly affects potency. Both
observations are supported by Schoeder et al. (2018) and
previous studies who noted that indazoles are more potent than
indoles but that replacing the p-fluorobenzyl moiety with a
pentyl chain gives compounds with similar receptor affinity and
similar potency. It is suggested that the ester moiety of MDMB-
FUBINACA (20), which is also present in AMB-FUBINACA
(2), then forms polar interactions with the H1782.65 region
of the receptor (Kumar et al., 2019). AB-FUBINACA (1) has
an amide moiety in this position rather than an ester, which
could also create polar interactions and has a similar potency
to AMB-FUBINACA (2) in this study. This suggests that as
with the fluorobenzyl/fluoro-alkyl chain in the “narrow side
pocket” region, the methyl ester/amide moiety may influence
ligand affinity rather than receptor activation. The “bulky”
tert-butyl moiety of MDMB-FUBINACA (2) produces a more
potent compound than the closely related AMB-FUBINACA
(3) suggesting that it is this region, when all other structural
features are in place to ensure ligand affinity, which is involved
in receptor activation and therefore influences potency. AB-
FUBINACA (1) and AMB-FUBINACA (2) both have a dimethyl
group in this region and both have an indazole core and so have
similar potency. Chirality will affect the relative positions of the
functional groups within this region and most likely, as a result,
will affect their interaction with receptor binding and activation
sites. Potency is more conserved for the (R)-AMB-FUBINACA
than for (R)-AB-FUBINACA and so the amide moiety may be
affecting both ligand affinity and receptor activation in this spatial
arrangement to a greater degree than the ester moiety. In this
study 5F-MDMB-PINACA (3) is the only compound with, like
MDMB-FUBINACA (20), a tert-butyl and ester moiety. The (S)-
enantiomer is the most potent compound studied here and the
(R)-enantiomer is 70 times less potent. It appears that retention
of potency in the (R)- enantiomer is greater if there is a valinate
methyl ester configuration rather than a valinamide, leucinamide
or tert-leucine methyl ester configuration.
Chiral HPLC Separation Method
Development
The underlying mechanisms of the chiral selectivity of a chiral
stationary phase (CSP) have been reviewed by Berthod (2010).
Selectivity is believed to occur as a result of a differential
three-point interaction between the enantiomers and the CSP.
Chiral separation is based on the formation of intermediate
diastereoisomeric complexes between the CSP and the
enantiomers in the racemic mixture. One enantiomer will
have a three-point interaction with the CSP and the other
a two-point interaction based on the spatial arrangement of
the molecule around the chiral center. As the interactions are
still relatively poorly understood, the prediction of the best
CSP for a given racemate normally relies on past experience
of similar tested compounds or trial and error. As the SCRAs
are neutral molecules, the variation of the pH at which the
separation occurs has little influence on chromatographic
selectivity. The results of the initial column screening tests are
shown in Table 2. The Lux R© Amylose-1 (Amylose tris(3,5-
dimethylphenylcarbamate)) and Lux R© i-Cellulose-5 (Cellulose
tris(3,5-dichloro-phenylcarbamate)) columns provided the
greatest selectivity for the SCRAs tested (AB-CHMINACA (4)
enantiomer standards were not available for the initial CSP
screening experiments). The dimensions of these columns were
optimized and 3µm, 2.1 × 150mm columns containing each
phase were selected for further evaluation and optimization
in reverse phase mode. The same CSP in a different column
format, CHIRALPAK R© IA-3 (3µm, 4.6 × 250mm; Amylose
tris(3,5-dimethylphenylcarbamate) immobilized on 3µm silica
gel), has previously been used to separate MDMB-CHMICA
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TABLE 2 | Preliminary Screening of Phenomenex Lux® Chiral HPLC columns for indazole-3-carboxamide synthetic cannabinoid enantiomer separation.
Chiral HPLC column Coated or immobilized
on silica gel?
Chiral stationary phase (CSP) Resolution between
Enantiomer pairs using 50:50 MilliQ:ACN isocratic method a
AB-FUBINACA 5F-MDMB-PINACA AMB-FUBINACA
Lux® Amylose-1,
100 × 4.6mm, 5µm
Coated Amylose
tris(3,5-dimethylphenylcarbamate)
3.20 2.46 1.21
Lux® Cellulose-1,
100 × 4.6mm, 5µm
Cellulose
tris(3,5-dimethylphenylcarbamate)
0.59 0.49 0.00
Lux® Cellulose-2,
100 × 4.6mm, 5µm
Cellulose tris(3-chloro-4-
methylphenylcarbamate)
3.00 0.57 0.93
Lux® Cellulose-3,
100 × 4.6mm, 5µm
Cellulose tris(4-methylbenzoate) 0.00 0.13 0.11
Lux® Cellulose-4,
100 × 4.6mm, 5µm
Cellulose tris(4-chloro-3-
methylphenylcarbamate)
2.69 0.00 1.45
Lux® i-Cellulose-5,
150 × 4.6mm, 5µm
immobilized Cellulose
tris(3,5-dichlorophenylcarbamate)
3.55 1.51 0.62
(12) and MDMB-CHMCZCA (13) enantiomers in normal phase
mode (Andernach et al., 2016; Weber et al., 2016). Doi et al.
(2016, 2018) also reported on the use of an amylose-based chiral
selector CHIRALPAK R© AZ-3R (3.0µm, 2.1 × 150mm; amylose
tris(3-chloro-4-methylcarbamate) column) in reverse phase
mode to separate carboxamide-type SCRAs.
For the columns selected for further study, there was no
difference in chromatographic performance as a result of using
either methanol or acetonitrile as an injection solvent. The
addition of 0.1% formic acid to the mobile phase solvents had
negligible effect on selectivity and chromatographic performance,
meaning that the method could be transferred to an HPLC-PDA-
QToF-MS/MS system without further adaptation. Preliminary
investigations suggest that both columns lose their selectivity
when methanol is used instead of acetonitrile as a mobile
phase component.
The separation of all four enantiomer pairs on the Amylose-
1 column and the i-Cellulose-5 column using either an
45:55 or 55:45 (H2O:ACN) isocratic method is shown in
Figures 4A,B. Table S1 details the chromatographic parameters
[described succinctly by (Chromacademy, 2018)] for both
columns using mobile phase compositions of 45:55, 50:50, and
55:45 (H2O:ACN) operating in isocratic mode. Although less
efficient than the Lux R© i-Cellulose-5, the Lux R© Amylose-1
column demonstrated greater selectivity and chromatographic
performance for SCRA racemates containing terminal methyl
esters (AMB-FUBINACA (2) and 5F-MDMB-PINACA (3)) and
with the (R)-enantiomer eluting before the (S)-enantiomer for all
compounds. This is consistent with previously reported chiral
separations of similar terminal methyl ester-containing SCRA
racemates on amylose-based CSPs (Andernach et al., 2016; Doi
et al., 2016, 2018; Weber et al., 2016). In contrast, the Lux R© i-
Cellulose-5 column demonstrated greater selectivity for SCRA
racemates containing a terminal amide moiety (AB-FUBINACA
(1) and AB-CHMINACA (4)). For three of the four compounds
the order of elution was reversed on this column, with (S)-
enantiomers eluting first, except for 5F-MDMB-PINACA (3)
enantiomers, which retained the same elution order ((R) then (S))
observed on the Lux R© Amylose-1 column. This is the first time
a cellulose-based CSP has been reported for the fully resolved
separation of SCRA racemates. During the initial screening
process (Table 2), the cellulose-based CSPs that contained a
chlorinated CSP (e.g., Lux R© Cellulose-2 and−4 and Lux R© i-
Cellulose-5) all showed good selectivity for the AB-FUBINACA
(1) enantiomers but the non-chlorinated cellulose-based CSP,
Lux R© Cellulose 1 and 3, were not selective. Doi et al. (2016)
previously investigated a CHIRALPAK R© OD3 cellulose-based
CSP column (cellulose tris(3,5-dimethylphenylcarbamate)) for
two methyl ester-containing SCRAs, resulting in poor resolution;
however, no SCRAs with terminal amidemoieties were tested and
the CSP selected for testing did not include a chloride moiety.
This indicates the importance of the chloride-SCRA terminal
amide interaction with this CSP and its role in selectivity. Such
knowledge of the separation mechanisms of SCRA enantiomers
will aid the choice of CSPs for future studies as new chiral SCRAs
emerge onto the illicit drug market.
Achiral Analysis of Seized Samples
The seized samples described in this study had undergone
preliminary qualitative analysis by GC-MS (unpublished data).
No samples obtained byMANDRAKE between 2017 and January
2018 were found to contain AB-FUBINACA (1), first detected
in Japan in 2012 (Uchiyama et al., 2013) or AB-CHMINACA
(4), first detected in 2014 (EMCDDA, 2017c). The production
and export of these compounds were controlled in China in
January 2015 (UNODC, 2015) and internationally controlled in
November 2018 (UNODC, 2018c). AMB-FUBINACA (2) and
5F-MDMB-PINACA (3) were controlled by China in September
20181 (UNODC, 2018b). Samples were pre-selected to contain
either 5F-MDMB-PINACA or AMB-FUBINACA in order to
carry out a preliminary study on (R)-enantiomer prevalence in
seized samples.
1https://www.thepaper.cn/newsDetail_forward_2389954 (accessed February 2,
2019).
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FIGURE 4 | HPLC-PDA chromatograms showing the resolution of indazole-3-carboxamide synthetic cannabinoid receptor agonists on (A) a Lux® Amylose-1 column
and (B) a Lux® i-Cellulose-5 column. Mobile phase components: A-H2O, B-Acetonitrile. Compound numbering relates to that provided in Figure 1.
The results of the qualitative and quantitative analysis of the
selected seized samples are described in Table 3 and in Figure 5.
In order to estimate herbal material heterogeneity, samples were
not homogenized prior to extraction. There was variability in
the concentrations detected in the replicate samples, reflecting
the inherent heterogeneity of such herbal materials, with 2
to 3-fold differences in concentration being detected in single
samples. This is likely to add to variability in the effects on the
consumer if the materials are subsampled for use by consumers
at different times and so therefore, from a harm reduction and
risk assessment context it is helpful to analyse and report such
samples in this way.
5F-MDMB-PINACA (3) was detected by GC-MS as the
only SCRA present in six samples and as part of a mixture in
two samples. The concentrations of 5F-MDMB-PINACA in
the samples ranged from <1.0 to 91.5 mg/g herbal material
(<0.1 to 9.15% w/w herbal material). It was a minor SCRA
component in one sample, where it was detected with
AMB-CHMICA (16) (methyl 2-(1-(cyclohexylmethyl)-1H-
indole-3-carboxamido)-3-methylbut-anoate), also known
as MMB-CHMICA. AMB-CHMICA has previously been
determined to be six times less potent than 5F-MDMB-PINACA
(Banister et al., 2016). 5F-MDMB-PINACA (3) was also
present as a trace component (<1 mg/g, <0.1% w/w herbal
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FIGURE 5 | Concentrations of synthetic cannabinoid receptor agonists (SCRAs) seized in Manchester, UK. Shaded areas denote samples where a semi-quantitative
result has been calculated for a compound based on the detector response for AMB-FUBINACA.
material) of a mixture with ADB-CHMINACA (17) (N-(1-
amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)
indazole-3-carboxamide), also known as MAB-CHMICA,
and traces of tentatively identified 5F-ADB-PINACA isomer
2 (18) (N-(1-amino-3,3-dimethyl-1-oxo-2-butan-2-yl)-1-(5-
fluoro-pentyl)-1H-indazole-3-carboxamide). Interestingly,
ADB-CHMINACA (17) has been demonstrated to be equipotent
with 5F-MDMB-PINACA (3) (Banister et al., 2015a).
AMB-FUBINACA (2) was detected in six samples, in
five as the only SCRA present and in one sample mixed
with the closely structurally-related SCRA, EMB-FUBINACA
(10) (ethyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-
3-methylbutanoate). The concentrations of AMB-FUBINACA
(2) ranged from 15.5 to 58.5 mg/g herbal material (1.55–5.85%
w/w herbal material). AMB-FUBINACA (2) was previously
detected in a product known as “AK-47 24 Karat Gold,” which
was implicated in an acute toxicity event in New York in 2016
(Adams et al., 2017). Replicate analysis of a single packet of the
material in this case gave a result of 16.0 +/– 3.9 mg/g (1.6%
w/w herbal material). Five of the seized samples reported in
this study were seized on the same day in the same area as
each other and all contain relatively similar concentrations of
AMB-FUBINACA (range 22.8–58.5 mg/g herbal material). Semi-
quantitative estimates have been provided for the concentrations
of AMB-CHMICA (16), ADB-CHMINACA (17) and EMB-
FUBINACA (10) in the samples. As such, the data should be
treated as indicative only.
As well as the GC-MS data, the molecular mass and
fragmentation patterns of these compounds were confirmed by
HRMS analysis (see Table 3), with reference being made to
previously published comparative data on the same compounds
(Carlier et al., 2017a,b; Liu et al., 2017; Mardal et al., 2018).
All mass assignments agreed within 4.1 ppm with calculated
theoretical monoisotopic masses (Table 3).
Chiral Analysis of Seized Samples
Enantiomer ratios were determined using the relative peak
areas of the chromatographically resolved enantiomers rather
than a calibration curve due to the very large difference in
concentrations of each enantiomer detected in the samples
(Table 3). Due to its wide linear range, the PDA detector response
at 210 nm was used for this purpose. It was found that the
calculation of the enantiomer ratio using the HRMS response
led to an over-estimation of the contribution of the minor (R)-
enantiomer. This was confirmed by analysis of 10-, 100-, and
1,000-fold dilutions of the original extract. The HRMS detector
was used for confirmatory purposes and ToF-MS, MSe and
MS/MS data provided confirmation of enantiomer identification
in addition to retention time matching to a racemic reference
standard (see Figure 6 for examples of AMB-FUBINACA (2) and
5F-MDMB-PINACA (3) enantiomer identification). The ratio
calculated using the PDA detector remained constant over the
dilution range and the ratio calculated using the HRMS detector
decreased with increasing sample dilution. The chiral profiles
of AMB-FUBINACA (2) and 5F-MDMA-PINACA (3) and in
16 seized herbal materials are shown in Table 3. The limited
chiral profiling studies carried out to date on seized SCRAs
have reported the expected and overwhelming prevalence of the
(S)-enantiomers in recovered samples (Andernach et al., 2016;
Doi et al., 2016; Weber et al., 2016). Some variation in the
Frontiers in Chemistry | www.frontiersin.org 14 May 2019 | Volume 7 | Article 321
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FIGURE 6 | Examples of the identification of SCRA enantiomers in seized samples by Chiral UPLC®-QToF-MS/MS (A) sample 11 containing 5F-MDMB-PINACA and
(B) sample 12 containing AMB-FUBINACA. The most important accurate mass data has been enlarged in the spectra provided for ease of viewing.
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FIGURE 7 | Estimated intrinsic potency values, calculated using equation 1 and/or equation 2, from replicate analyses (n = 3) of alleged “spice” samples seized in
Manchester, UK. Shaded areas identify samples for which estimated intrinsic potency values have been calculated. Intrinsic potency values for sample 2 (see Table 3)
have not been calculated due to insufficient sample for quantitative analysis. Sample 10 (see Table 3), in which both AMB-FUBINACA and EMB-FUBINACA were
detected has also been omitted as no comparative data for potency (EC50) is currently available for EMB-FUBINACA.
enantiopurity of precursors may occur as a result of variation
in the supply chain and could therefore be utilized in SCRA
batch profiling if such variation were reproducible within a
production batch or supplier. L-tert-leucine, the precursor of 5F-
MDMB-PINACA (and other leucine-derived SCRAs as well as
licit pharmaceuticals such as antiretroviral protease inhibitors
e.g., Atazanavir, Boceprevir, and Telaprevir) is widely available
and is produced efficiently on an industrial scale with a high
degree of enantiopurity (>99%) (Xue et al., 2018).
In this study, as expected from previous studies and as
a result of the lower cost and the relative availability of the
relevant precursors, the more potent (S)-enantiomer of 5F-
MDMB-PINACA (3)was themajor enantiomer, present at>93%
in all samples analyzed and in the majority at >99%. (S)-
AMB-FUBINACA (2) was present at 96.8–98.2 % in the small
sample set examined. An (almost) identical ratio was obtained
for the 5 samples seized on the same day, with this ratio being
distinct from the other sample, indicating that chiral profiling
may be a useful additional tool in distinguishing batches of
valine methyl ester-derived SCRAs at a synthetic source level
even though the absolute size of the variation in chiral profiles
is small.
Estimated Intrinsic Potency of Seized
Samples
We propose that the intrinsic potency of one SCRA containing
sample relative to another can be estimated using the CB1
potency of each compound detected, relative to the control
sample used in the bioassay (in this case JWH-018) and the
concentration of each SCRA, with a correction factor applied
for enantiopurity where such information is available. The
calculation of such an estimated intrinsic potency provides a
simple methodology for comparing the relative potential for
harm of different sample batches containing a number of SCRA
compounds at different concentrations for risk evaluation, harm
reduction and/or intelligence purposes. This approach is a
method of comparing samples before they are consumed and
does not directly indicate the physiological/toxicological effects
that would be experienced by a user following exposure. The
estimated intrinsic potency calculation does not currently take
into account the potential effect of differences in CB1 efficacy
between the SCRAs. Within this study, the range of Emax values
calculated for the different (S)-enantiomers was relatively small
(267–331%), therefore the inclusion of the Emax values in the
estimated intrinsic potency calculation would have a limited
effect on the differentiation of seized samples. It should be
noted, though, that comparing Emax values (as a measure of
efficacy) from different studies can result in different outcomes.
Sachdev et al. (2018) have developed an interesting approach
to compare the efficacy of SCRAs (also taking into account
the potential “assay ceiling” issue), which could also be used
in this method to assess the potency of seized samples. User
response will be affected by a number of additional factors,
including user tolerance, the presence of other co-consumed
substances and the influence of the mode of use of the drug e.g.,
smoking vs. vaping vs. ingestion. During smoking, active and
inactive pyrolysis products may be produced which would then
be inhaled (Kevin et al., 2019). The physiological response of a
user to a sample could also be affected by the rate of metabolism
of the parent SCRA(s) following exposure, the formation of
pharmacologically active metabolites (Cannaert et al., 2016;
Gamage et al., 2019) and the relative ability of both parent and
metabolites to pass the blood-brain barrier to exert their CB1
mediated psychoactive effects.
Keeping in mind the above-mentioned limitations, the
estimated intrinsic potency of the SCRA-containing sample can
be calculated as described in Equations (1) and (2).
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When the relative proportions of the enantiomers have not
been determined:
Estimated Intrinsic Potency =
[(
CB1 EC50, JWH−018
CB1 EC50, SCRA
)
x ConcSCRA
]
100
(1)
When the relative proportions of the enantiomers have been
determined they can be used to adjust the estimated intrinsic
potency value:
Estimated Intrinsic Potency
=
[(
CB1 EC50, JWH−018
CB1 EC50, SCRA
)
x P(S)
]
+
[(
CB1 EC50, JWH−018
CB1 EC50, SCRA
)
x P(R)
]
∗ConcSCRA
100
(2)
Where,
EC50 values are expressed in nM, ConcSCRA is the
concentration (mg/g) of a particular SCRA detected in the
sample, P(S) is the proportion of the (S)-enantiomer present in
the sample e.g., 93.6% = 0.936, P(R) is the proportion of the
(R)-enantiomer present in the sample e.g., 6.4%= 0.064.
When multiple SCRAs are present in a single sample the term
on the top line is simply repeated for each SCRA detected and
added together. A combination of the two equations can be used
when chiral data is available for some SCRAs but not for others.
The estimated intrinsic potency values have been calculated
for the samples seized in this study which contained either
5F-MDMB-PINACA or AMB-FUBINACA (Figure 7) and
the underlying data and calculations are provided in
Tables S2, S3a,b. To illustrate how such an approach could
be used when multiple SCRAs are present in samples, an
estimated intrinsic potency value has been calculated for
compounds which have been quantified on a semi-quantitative
basis and whose potency (EC50) has not been determined
directly in this study. For example, 5F-MDMB-PINACA and
AMB-CHMICA were both detected in sample 1. As no EC50
data is available for AMB-CHMICA from this study, the EC50
for 5F-MDMB-PINACA was used and a correction factor
applied. This correction factor was derived from data reported
by Banister et al. (2016) who have previously determined the
EC50 values for both compounds: correction factor = (EC50,
5F−MDMB−PINACA / EC50, AMB−CHMICA) = (0.59/3.59) = 0.164.
ADB-CHMINACA was detected in sample 6 and the EC50 value
relative to JWH-018 was calculated using the data reported
previously by Cannaert et al. (2017). As no relative potency data
is available for EMB-FUBINACA, either to another compound
in this study or to a JWH-018 control sample run using the same
assay, no intrinsic potency values were calculated for sample 10
which contained both AMB-FUBINACA and EMB-FUBINACA.
The estimated intrinsic potency varies even within this small
sample with its limited variability of SCRA compounds (Figure 7
and in Table S2). The samples with the lowest estimated intrinsic
potency in this study are up to 10 times less potent than the most
potent samples. Coupled with the heterogeneous nature of the
herbal samples this will inevitably lead to unpredictable effects
experienced by the user(s). The visual characteristics of SCRA
infused materials give no indication of the SCRAs present, their
concentration or their relative potency.
We propose that bioassay data on pure compounds (and
where available, data on the prevalence of both the (R)- and
(S)-enantiomers), is compiled for existing and emerging SCRAs
to allow the calculation of estimated intrinsic potency values as
a standard practice for evaluating and comparing the potential
harms of SCRA containing materials. If present, signaling
bias caused by different SCRAs may affect the accuracy of
estimated intrinsic potency and so this also warrants further
study. Alternatively, the bioassay could be used as a standalone
assessment technique to determine a samples EC50 without the
necessity for identification of the SCRA components or their
concentrations. Either way, the calculation of an intrinsic potency
value allows independent samples, containing different SCRAs
with inherently different potencies (as expressed by the EC50) at
different concentrations to be compared directly with each other.
This may be a useful tool in expressing differences in the relative
potential harms of seized samples.
CONCLUSIONS
In this study, we have described the investigation of the effect
of chirality on the potency and, for the first time, efficacy,
of four indazole-3-carboxamide SCRAs. All (S)-enantiomers
were more potent than their respective (R)-enantiomers at
both CB1 and CB2 although the scale of the difference
varied greatly between compounds. (S)-enantiomers had up
to three times greater efficacy at CB1 but had similar or
lower efficacy at CB2 than their respective (R)-counterparts.
To assess the prevalence and variability of (R)-enantiomers
of SCRAs in seized samples, an analytical method was
developed for the separation of SCRA enantiomers. With an
increased knowledge of chiral column retention mechanisms
and selectivity, we have recommended two column types,
depending on the structural features of the SCRAs studied.
With such knowledge, methods can be selected and adapted
as new chiral SCRAs enter the market. We have successfully
applied the method to a small number (n=16) of seized samples
in a preliminary study where all SCRAs present have been
identified and quantified where possible. It is recommended
that amylose-based CSPs are used for the analysis of SCRAs
with terminal methyl esters (e.g., 5F-MDMB-PINACA andAMB-
FUBINACA in this study) and that cellulose-based chlorinated
CSPs are used for those compounds with terminal amides
(e.g., AB-FUBINACA and AB-CHMINACA in this study).
A considerably larger set of samples will be analyzed in
future to determine within and between batch variation of
chiral profiles and their potential discriminatory power in
case samples.
We have proposed a methodology for calculating the
estimated intrinsic potency of a drug sample as presented
to a user, prior to use. Due to the utilization of different
signaling pathways in different in vitro bioassays for the
evaluation of potency and efficacy of SCRAs at CB1 and
CB2 receptors, we recommend further investigation of the
possible impact of SCRA signaling bias on the estimated
intrinsic potency approach introduced in this study. A
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direct comparison of the in vitro response of the bioassay
to both G-protein and β-arrestin mediated pathways in the
same assay or between independent assay systems (e.g.,
the assay used in this study vs. FLIPR membrane potential
assay vs. GTPγS binding assay vs. cAMP accumulation
assays) is recommended. At present the estimated intrinsic
potency calculated for a sample does not take into account
the efficacy of the SCRAs present and this warrants
further investigation.
Further experiments could investigate the effect of chirality on
SCRA potency and efficacy using the following compounds and
their enantiomers: (S)- and (R)-MDMB-FUBINACA vs. (S) and
(R)-AMB-FUBINACA and (S)- and (R)-5F-MDMB-PINACA vs.
(S)- and (R)-5F-AMB-PINACA. Such a study would further
enhance our understanding of the mechanism of SCRA-CB1
receptor interactions.
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